Telix Pharmaceuticals is trading at $10.05 (-9.95%) following Q3 update-related selling; a report said investors were spooked, though the decline mostly appeared to reflect profit-taking and positive news already priced in. - Q3 revenue rose 19% year over year but fell 1% quarter over quarter; Precision Medicine revenue was flat sequentially. - Full-year R&D spending guidance narrowed to US$240 million–US$260 million. Full-year revenue guidance above US$1 billion was reaffirmed, tracking toward its upper end.